Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Q3'24

By Inderes11/8/2024, 9:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:01 - 10:18

Thank you. Operator. Good morning, and a warm welcome to Egetis Therapeutics webcast for the quarter three report and results. For those who haven't had the privilege to meet before, my name is Nicklas Westerholm, and I am the CEO of the company. With me today, I also have our CFO, Yilmaz Mahshid, Karl Hård, our Head of Investor Relations and Business Development, and Henrik Krook, our Head of Commercial Operations globally. What we were planning to cover today are updates on several important milestones delivered during the quarter. We will touch upon the progress of our Marketing Authorization application for Emcitate with the EMA, and the guidelines for Diagnosis and Management of MCT8 deficiency issued in July by the European Thyroid Association. The new data was published through an abstract concerning survival. The data was presented at the 46th Annual Meeting of the European Thyroid Association in September. The ReTRIACt trial status is obviously important, recognizing that it is a pivotal randomized controlled study for the US submission. We'll also touch upon the patent application we submitted to the US Patent and Trademark Office regarding the process of preparation of tiratricol, and also touch upon the news that will feature during October and early November, which was the directed share issue of around 30 million USD. We'll then move into a financial update from Yilmaz Mahshid and then subsequently move into Q&A from the audience. So starting off with the marketing authorization application for the approval in the European Union, we are very pleased to call out that we remain on track according to the EMA's stipulated timelines. As many of you would know, the marketing authorization application was submitted in October last year, and subsequently, we received the 120-day questions in February, which we responded to in August. Subsequent to that, as per the stipulated timelines, we received on the 17th of October, the day 180 questions, and planned to respond to these by November 12th, i.e. beginning of next week. According to EMA's published procedural timelines. Published procedural timelines. Subsequent to that. The ball is, of course, in the EMA's court, but we are looking forward to a CHMP opinion towards the end of this year or early next year. Along the lines of Europe, we also had some guidelines that were issued in July. The guidelines were issued by the European Thyroid Association (ETA) covering diagnosis and treatment of Emcitate deficiency, among others. This is somewhat unusual, recognizing that Emcitate deficiency is an ultra rare condition with no therapy approved to date. These guidelines recommend the use of tiratricol or Emcitate as a long-term therapy for all patients with MCT8 deficiency, but also for certain patients with a different indication, such as resistance to thyroid hormone beta (RTH-beta). This is, of course, valuable for us moving forward; it will be important for commercialization in Europe, where clear guidelines now exist and will also support the management of this disease. Page two. Some new data that was published in more detail. So this data derives from a retrospective research study by the Erasmus Medical Center in Rotterdam, where they investigated the effects of tiratricol on mortality in patients with MCT8 deficiency. The abstract was published ahead of the European Thyroid Association meeting, and the data presented is extremely valuable for us. It illustrates that tiratricol treatment had an approximately three times lower risk of all-cause mortality, which is, of course, very much to our benefit. Moving ahead, especially when it comes to payer interactions in Europe, as well as the forthcoming US drug application. On top of that, a peer-reviewed publication is in progress, which will hopefully be published at the beginning of next year. Turning our attention to the ReTRIACt study, where we have had better progress in quarter three compared to previous quarters, which is very important to underline. As a reminder, this study was agreed upon with the US FDA. A pivotal, randomized, placebo-controlled study in at least 16 evaluable patients with MCT8 deficiency to support the NDA. We all recognize, and we need to be humble, that the recruitment in previous quarters hasn't been up to our expectations and to increase the recruitment study during the summer, we added three additional clinical study sites. Commercial study sites, which were opened in July in the US, one in Texas, one in Georgia, and one in North Carolina. So at this moment, we have six study sites open, two in Europe and four in the US. The current study status includes the two patients we expected to be randomized, which we highlighted in our quarter two report. Furthermore, the six patients planned for screening, which were also mentioned in the quarter two report, resulted in four new patients that are now in the running period. So in total, we now have 17 patients included, of which eight patients are available and four patients are in the so-called running period. Please note here that, as with any clinical study, there will be a few drop-outs and hence not all patients included will be randomized. Going forward, we have more than ten eligible patients identified and remaining for recruitment, of which a couple of patients are already scheduled for screening in the coming weeks. As previously communicated, we have full focus on the recruitment for the ReTRIACt study, and we will update the market as soon as the recruitment for the study is closed. At that point, we'll also be able to provide information on expected top-line results and when we plan to submit a new drug application. Moving on to our patent application. As many of you know, today it holds orphan drug designation. ODD for Emcitate for the treatment of Emcitate deficiency, as well as RTH-beta, both in the US and Europe. That provides marketing exclusivity of seven years in the US and ten years in Europe, respectively, from the dates of regulatory approval. We were very pleased with the submission of our first patent application concerning processes of preparation for tiratricol and, in layman's terms, manufacturing patents. If granted, this would be a significant patent and important for us. Generally, the exclusivity term of a new patent is 20 years from the date on which the patent application for the specific patent in question was filed in the US. Let's turn our attention to our directed share issue. We announced the share issue. The directed share issue occurred on the 30th of September. And this was a directed share issue for approximately 30 million USD, or 300 million Swedish kronor. The directed share issue was oversubscribed and included both existing and new international and Swedish institutional investors. We are very proud, considering the challenging market conditions, that we executed this. The subscription price was at market value, and more importantly, the directed share issue was led by Frazier Life Sciences with 10 million, or roughly a third of the share issue, executed on their behalf. So with that, let's turn our attention to the financials for the quarter. And I hand over to our CFO, Yilmaz Mahshid. Please go ahead.

Yilmaz Mahshid
10:18 - 12:39

Thank you. Nicholas. Looking at the numbers, revenues for the first nine months of the year were 35.3 million Swedish kronor, versus 25 million SEK in the same period last year. Revenues for the third quarter of the year were 9.4 million Swedish kronor, versus 12.2 million SEK in the same period last year. The lower numbers in the quarter compared to the same period in 2023 are due to inconsistent order patterns from countries where the drug can be reimbursed at the pre-approval stage. Results after tax for the third quarter of the year were -86.2 million, which was also the same number in the same period last year. Operating cash flow for the third quarter of the year was -62.5 million, versus 93.1 million in the same period last year, and the cash position at the end of September was approximately 130 million Swedish kronor, versus 85 million Swedish kronor at the end of the same period last year. And as Niclas mentioned, it was very gratifying to see that we have good support from existing and new shareholders, which resulted in a net cash injection to the company of 282 million Swedish kronor that occurred post the period close. And while mentioning cash, I would also like to highlight that Emcitate has been granted rare pediatric disease designation, which gives it the opportunity to receive a Priority Review Voucher in the US upon approval. As a guide to your modeling regarding the cash position for the company, the base case should be that we will transact and sell the PRV. The public figures, as many of you probably are aware, for the last two transactions of PRV are in the range of 150 to 158 million USD. This would equate to approximately 1.6 to 1.7 billion Swedish kronor at the current dollar value, of which we are eligible for 50%. With that, I would like to hand back to Niklas.

Nicklas Westerholm
12:40 - 12:51

Thank you very much, Yilmaz, for the financial overview. And that takes us to the end of our presentation. And I'll hand over to the operator for question and answers. Operator, please.

Operator
12:55 - 13:15

If you wish to ask a question, please dial pound five on your telephone keypad. To enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Chan Sin Lee from Pareto. Please go ahead.

Unknown 1
13:17 - 13:46

Thank you. Good morning, and thanks for the presentation. So, I have a few questions. So regarding the US trial, you have included 17 patients, eight have completed, and four are in the running phase. Does this mean that the five patients have dropped out, or are they still subject to screening, and for those who dropped out, is there a reason you can possibly share? Is there any reason that you can possibly share?

Nicklas Westerholm
13:48 - 15:15

Good morning, Sharon. Thank you for your question. And I think I'll reiterate what I said before just to set the scene. Yes, we have made good progress. And during quarter three, when it comes to recruitment, as we called out in the second quarter report, the two patients we were planning to be fully randomized have been fully randomized. We were planning to screen six patients. Those six patients were screened and led to four patients in the running period. You're absolutely right when it comes to dropouts; as in any study, one will have dropouts. It's fair to assume that the dropout rate would be around 20% when it comes to screening patients. Being a study on dropouts, I need to be very, very clear here that the dropouts are not related to the study drug. As you can imagine, I can't give specifics about individual patients, but it could be related to things like an illness in the family, where the parents or caregivers, subsequently, didn't have the bandwidth for their children to continue in the study. So I think it's very important to recognize, yes, we have had dropouts and we'll most likely continue to have dropouts. But it's not driven by the drug.

Unknown 1
15:18 - 15:56

Okay. Thank you. Yes, that's pretty clear to me. And also a question regarding the European process. So regarding the day 180 list of questions that you plan to submit next week, could you share a bit? Is there anything unexpected that you received from the EMA? Or do you believe it would be just some minor issue? And if the European approval stays on track, let's say it's later this year or early next year. So what would be the go-to-market strategy in Europe? Thank you.

Nicklas Westerholm
15:57 - 17:04

Thank you. And yet another good question. And you are rightly so, that on the 17th of October, we received the 180 list of outstanding questions or issues. We plan to respond to these according to the stipulated timelines, i.e., 12 of November. November 12. One can conclude that since we are not requesting an extension, these questions are certainly manageable. I really want to thank the whole team in Egetis for their outstanding work in responding to the 120-day questions in Europe, because that removed a lot of the concerns, potential concerns or questions the EMA had. So I see personally that based on the list of the 180-day questions we received in October, we have a path forward without any surprises to a CHMP opinion. And then I missed the second part of your question. If you don't mind repeating that.

Unknown 1
17:05 - 17:10

So yeah, what will be the go-to-market strategy in Europe once it's approved?

Nicklas Westerholm
17:11 - 18:30

Yeah. The go-to market strategy is very simple and does not differ compared to other companies. When commercializing in Europe, one should recognize that post the CHMP opinion, it's up to 67 days until you get the European Commission approval. So one can't commercialize until after that. Then, like many other companies, we will initially focus on the EU markets of Germany, France, Italy, and Spain, and engage in parallel reimbursement dialogues. Obviously, the country where we can recognize sales earliest, as with any other company, is in Germany. There, as I'm sure you are familiar, there is free pricing during commercialization while discussions of reimbursement are ongoing for up to 12 months. So that's our go-to-market strategy. And then subsequent to that, of course, Italy, France, Spain. I can't give you guidance on exactly how long the reimbursement period will take there. It will take time, but it's roughly 1 to 2 years. And in parallel, then we, of course, will go broader after the reimbursement dossiers have been submitted in the EU for the rest of Europe.

Unknown 2
18:33 - 18:35

Okay. Perfect. Thanks for taking my question.

Nicklas Westerholm
18:36 - 18:39

Thank you, Shane. And we can move on to the next question.

Operator
18:42 - 18:47

The next question comes from Oscar Hoffenblum from Bryan Garnier. Please go ahead.

Unknown 3
18:49 - 19:08

Hi, Timo. Congrats on the execution. My question concerns the survival data that you have published. I was just wondering if this is something that could eventually end up in the label, and ultimately, if in your view, this could impact the pricing negotiations with the authorities both in Europe and in the US. Thank you.

Nicklas Westerholm
19:10 - 20:03

Yeah. No, that's a really good question. And obviously, I can't share too much about the data because the peer-reviewed publication is not yet available. And as I expected and mentioned before, it will be out during the beginning of next year or the first half of next year. I think this is, of course, an important piece of the puzzle when it comes to pricing and reimbursement. So this will definitely be part of the dialogues we have in Germany, France, Spain, and Italy subsequent to European approval. So again, a very important piece of the puzzle. It's, of course, also an important piece of the puzzle in the forthcoming interactions with the FDA on the New Drug Application. So yes, to both of your questions, Oscar.

Unknown 3
20:05 - 20:24

Great. Thank you. And maybe just one additional small question. Um, I was wondering if you could provide any insights on the status of the patients that you have included in the trial, in terms of whether most of them were treatment naive or on treatment with Emcitate prior to the inclusion.

Nicklas Westerholm
20:25 - 20:51

Now, that's a good question. And it's a simple response to that. As we move forward with the recruitment and the progress, which I'm pleased with, we are improving the recruitment pace during quarter three. It's reasonable to assume that going forward, the majority of the patients included in the ReTRIACt study will be treatment-naive patients.

Unknown 3
20:55 - 20:57

Okay. Perfect. Thank you for taking my questions.

Nicklas Westerholm
20:58 - 21:01

Thank you. And let's move on to the next question.

Operator
21:04 - 21:09

The next question comes from Matthias Hågglund from Handelsbanken. Please go ahead.

Unknown 4
21:11 - 21:57

Yeah. Thanks so much. Matthias, I had a question about the recent transactions involving Priority Review Vouchers. I'm curious to hear your thoughts on why the value has stepped up from historically around 100 million US dollars to now 150 million US dollars. Obviously, we knew that potentially having access to one of those over time. Any thoughts from your side? What's been driving the 50% value increase? Step up. And then secondly, on the early access program in the US. Could you remind me about the recent progress with regards to that, to help me frame my expectations? What to expect from that going forward. Thanks so much.

Nicklas Westerholm
21:58 - 25:17

Well, thank you, and very good questions, Mathias. And for the audience. And Yilmaz mentioned this as well, that due to the rare pediatric disease designation that we received a couple of years ago, we will be eligible for a priority review voucher at the point of approval. And this is, of course, very important for us. As Yilmaz mentioned, when it comes to future cash positioning and financing of the upcoming launches both in Europe and the US. This is very much driven by the value of the vouchers. PRV value has been very stable actually during 2021, 2022, and 2023, in the region of 100 to 110 million USD. What we have recently seen actually are the two latest PRVs that have been sold, amounting to $150 million and $158 million. And what has driven this hike, so to say, in the value of these vouchers, is usually driven by demand and supply. I can't speculate more than that, but that's how we see it, which of course plays somewhat in our favor for a potential divestment of a voucher in the US. Then, when it comes to your second question regarding the expanded access program, I think it has a bearing on the number of patients being identified in the US. We are very pleased to say that despite the small number of people we have on the ground, our disease awareness activities have been effective. We only have four employees in the US. As many of you are aware, we have made some really good strides, and the team has identified up to 100 patients diagnosed with MCT8 deficiency in the US over the last 12 to 18 months, which is, of course, very important for potential approval and commercialization as identifying as many patients as possible is crucial. Specifically, regarding the Early Access Program (EAP) in the US, we have ten sites open so far, and another eight sites are in process. The important thing here to recognize is that since the ReTRIACt trial is in focus to drive recruitment, we are very restrictive on adding new patients into the expanded access program. If they are not eligible for the ReTRIACt study. So we need to focus on the ReTRIACt study. Newly identified patients should be funneled into that for screening if they are not eligible for any specific reason. We will then, of course, transfer them over to the expanded access or early access program, driven by inclusion criteria such as age below four years, as an example. I hope that answered your question, Matthias. Questions.

Unknown 4
25:18 - 25:20

Perfect. Very helpful. Thanks so much.

Unknown 5
25:20 - 25:21

Thank you.

Operator
25:24 - 25:28

The next question comes from Frederick Thor from Redeye. Please go ahead.

Unknown 4
25:31 - 25:33

Hello and thank you. My first question was about the patent application.

Unknown 3
25:33 - 25:34

My first question was about.

Unknown 4
25:34 - 25:37

This patent application is about the.

Unknown 6
25:37 - 25:51

The processes of preparation. Can you give us some context to that patent or how useful it actually can be, and maybe compare it to how strong it is compared to the Orphan Drug Designation? Thank you.

Nicklas Westerholm
25:52 - 27:20

Yeah. No thank you, Frederick. It's a really good question. And just to reiterate what I said before, this is a pattern that resonates within the CMC and manufacturing space. Obviously, one needs to recognize that this is not a composition of matter patent. And that's driven, of course, by the fact that this molecule is an old one, discovered in the 50s. Having said that, it doesn't have equal strength. I would say we need to be humble about that. Compared to a composition of matter patent. What's important to recognize here is that we have made substantial improvements in the process, such as crystallization and impurity management. And that is really valuable going forward, as obtaining protection on this will, of course, help us from an exclusivity perspective. On top of that, it's also worthwhile recognizing that the drug substance manufacturing involves a couple of chemical steps, including high-energy reactions, and hence needs to be manufactured in a bunker. All in all, this is an important patent. It's not that we need to be humble. It's not as strong as a composition of matter patent. But it will definitely help us from generic penetration going forward, if approved. Of course. Thank you, Frederick.

Unknown 6
27:20 - 27:46

And yes, a final question if possible, ahead of the potential EU launch, have you received any feedback from payers or opinion leaders about the trial results, how much that impacts their view of the drug candidates, and their willingness to pay and so on? Or is it too early to say anything?

Nicklas Westerholm
27:48 - 29:29

No, I think that's a very good question and it comes back to the track record of results that we announced during the summer. And here. I think it's very, very important to say that, when it comes to the regulatory pathway, the results of the study do not implicate that, neither in Europe nor in the US; both agencies have been very clear that the regulatory pathway is driven by treatment on peripheral thyrotoxicosis and the clinical effects we've seen in that space. So that is very, very clear. The actual Phase II study was important though from a regulatory standpoint when it comes to safety. So establishing the safety profile in the younger patient population. And here, we obviously studied patients below 30 months of age, 22 of them. And that generated some very, very important safety data that was incorporated in the response to the 120-day question submitted in August. When it comes to pricing. We still expect that we will receive an orphan premium price both in Europe and in the US. When it comes to Europe, we expect some implications on price due to not being able to show neurocognitive development effects. But on the contrary, in the US our price assumptions still remain the same since pricing and reimbursement drivers are different.

Unknown 4
29:33 - 29:34

Thank you very much.

Nicklas Westerholm
29:34 - 29:40

Thank you, Frederic. And I think we have time for a final question from Joe from Orex.

Operator
29:42 - 29:46

The next question comes from Joe Hedden from RX Securities. Please go ahead.

Unknown 7
29:49 - 30:36

Good morning. Thanks for taking my questions and congratulations on the progress in the European procedure. Just a point of clarity on that, Nick. You said that you've got a path; if you respond to the day 180 list of outstanding issues on time, you have a pathway to a CHOP opinion. And can you say whether that is likely to happen in the December CMP meeting? And then just a second question on the compassionate use sales of the drug. I just noticed that, I think for the first time, the compassionate use sales have ticked down. And I just wondered whether that's a factor of the number of patients treated or the price that you're getting on those. Now, I know it's a minor thing, but just any details you can provide would be greatly appreciated. Thank you very much.

Unknown 8
30:36 - 30:37

Yeah, sure. No.

Nicklas Westerholm
30:37 - 31:49

And when it comes to the potential CHMP opinion, as I said, we received the day 180 questions on the 17th of October. We plan to respond to that next week, by the 12th of November at the latest. Obviously, subsequent to that, the ball is in EMA's hands and the CMP, they could come back with another batch of 180-day questions, or they could well move on to the 210-day review, which results in a CHMP opinion. So I don't want to speculate on that. Uh, but we are comfortable with the responses we have provided and will provide next week on the 180 day questions. So I don't want to speculate on that because that is somewhat dangerous, since it's out of our control when it comes to our managed access program here. Here, I think we should be very, very clear that in the quarter two report, we referred to around 220 patients being included in the managed access program. In quarter three. We have said above 220 patients. So numerically, we have.

Unknown 8
31:49 - 31:49

Seen an increase quarter on quarter.

Nicklas Westerholm
31:49 - 32:23

Increase quarter on quarter. What we tend to do, Joe, is really focus on reporting in detail, right. So, I wouldn't read too much into this. If you look at the run rate over the last two years, you have at minimum over ten patients per quarter being added. Then there are some fluctuations. And as I said before, also when it comes to newly identified patients in the US, we are prioritizing the ReTRIACt study rather than putting them on the expanded access program.

Unknown 7
32:29 - 32:41

Okay. That's great. Thanks. It's good to see it ticking up. But what happened to the Q3 revenue? I mean, I know it's not substantial, but it's the first time it has decreased. But shouldn't those two be tracking in line?

Yilmaz Mahshid
32:42 - 33:12

Yeah. Joe, thank you for your question here. Yeah. So we saw a little downtick in the revenues from the Managed Access Program. And I've had the same question for the commercial team. They don't see any trends in the ordering, etc. This is just the lumpiness when it comes to reimbursements, whether we get the orders from reimbursed countries or not, and from those patients. So we have not heard anything from the organization on trend changes.

Unknown 7
33:14 - 33:17

Okay. All right. Fair enough. Thanks. Thanks, Nick.

Unknown 8
33:18 - 33:19

Thanks, Joe.

Nicklas Westerholm
33:21 - 33:24

And that takes us to the end of the call. Operator, hand over to.

Operator
33:24 - 33:30

You this time. So I hand the conference back to the speakers for any written questions and closing comments.

Nicklas Westerholm
33:33 - 33:49

So with that, I will take the opportunity to thank the audience for participating in our webcast concerning our quarter three results report, and thank the team for participating on the GTI side and wish you all a happy Friday. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…